A Phase 1 interventional study of Molnupiravir in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of the study is to learn what happens to different forms of molnupiravir (MOV) medications in a healthy person's body over time when taken on an empty stomach or with food. Researchers will compare the amount of MOV in the healthy person's body over time when different forms of medications are given.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
- Has (BMI) ≥18 kg/m\^2 and ≤32 kg/m\^2.
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive molnupiravir reference capsule.
Drug: Molnupiravir
Participants receive molnupiravir Formulation 1.
Drug: Molnupiravir
Participants receive molnupiravir Formulation 1 after a high-fat meal.
Drug: Molnupiravir
Participants receive molnupiravir Formulation 2.
Drug: Molnupiravir
Oral Administration.
Also known as: MK-4482, MOV, LAGEVRIO, EIDD-2801
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of N-Hydroxycitidine (NHC) in plasma: Treatment A versus Treatment B
AUC0-inf of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Area Under the Concentration-Time Curve From Time Zero to last measurable timepoint (AUC0-last) of NHC in plasma: Treatment A versus Treatment B
AUC0-last of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Area Under the Concentration-Time Curve From Time Zero to 12 hours (AUC0-12) of (NHC) in plasma: Treatment A versus Treatment B
AUC0-12 of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 12 hours postdose
Maximum plasma concentration (Cmax) of NHC: Treatment A versus Treatment B
Cmax of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Time to maximum plasma concentration (Tmax) of NHC: Treatment A versus Treatment B
Tmax of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Apparent terminal half-life (t1/2) of NHC in plasma: Treatment A versus Treatment B
t1/2 of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Apparent Clearance (CL/F) of NHC in plasma: Treatment A versus Treatment B
CL/F of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Apparent volume of distribution during terminal phase (Vz/F) of NHC in plasma: Treatment A versus Treatment B
Vz/F of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
AUC0-inf of NHC in plasma: Treatment B versus Treatment C
AUC0-inf of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
AUC0-last of NHC in plasma: Treatment B versus Treatment C
AUC0-last of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
AUC0-12 of NHC in plasma: Treatment B versus Treatment C
AUC0-12 of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 12 hours postdose
Cmax of NHC in plasma: Treatment B versus Treatment C
Cmax of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Tmax of NHC in plasma: Treatment B versus Treatment C
Tmax of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
t1/2 of NHC in plasma: Treatment B versus Treatment C
t1/2 of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
CL/F of NHC in plasma: Treatment B versus Treatment C
CL/F of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Vz/F of NHC in plasma: Treatment B versus Treatment C
Vz/F of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
AUC0-inf of NHC in plasma: Treatment D versus Treatment A
AUC0-inf of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
AUC0-last of NHC in plasma: Treatment D versus Treatment A
AUC0-last of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
AUC0-12 of NHC in plasma: Treatment D versus Treatment A
AUC0-12 of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 12 hours postdose
Cmax of NHC in plasma: Treatment D versus Treatment A
Cmax of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Tmax of NHC in plasma: Treatment D versus Treatment A
Tmax of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
t1/2 of NHC in plasma: Treatment D versus Treatment A
t1/2 of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
CL/F of NHC in plasma: Treatment D versus Treatment A
CL/F of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Vz/F of NHC in plasma: Treatment D versus Treatment A
Vz/F of NHC in plasma will be determined.
Time frame: Pre-dose, and at designated timepoints up to 72 hours postdose
Number of participants who experience one or more adverse events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to ~ 38 days
Number of participants who discontinue study intervention due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to ~ 38 days
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2023 to primary completion in Feb 2023, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molnupiravir